Suzhou Total Current Liabilities from 2010 to 2024

688137 Stock   36.25  0.84  2.37%   
Suzhou Novoprotein's Total Current Liabilities is decreasing over the years with slightly volatile fluctuation. Overall, Total Current Liabilities is expected to go to about 51 M this year. Total Current Liabilities is the total amount of liabilities that Suzhou Novoprotein Scientific is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. View All Fundamentals
 
Total Current Liabilities  
First Reported
2010-12-31
Previous Quarter
50.1 M
Current Value
51 M
Quarterly Volatility
6.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Suzhou Novoprotein financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Suzhou Novoprotein's main balance sheet or income statement drivers, such as Net Interest Income of 28.2 M, Interest Income of 32 M or Interest Expense of 2.9 M, as well as many indicators such as . Suzhou financial statements analysis is a perfect complement when working with Suzhou Novoprotein Valuation or Volatility modules.
  
This module can also supplement various Suzhou Novoprotein Technical models . Check out the analysis of Suzhou Novoprotein Correlation against competitors.

Currently Active Assets on Macroaxis

Other Information on Investing in Suzhou Stock

Suzhou Novoprotein financial ratios help investors to determine whether Suzhou Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Suzhou with respect to the benefits of owning Suzhou Novoprotein security.